{"componentChunkName":"component---src-pages-palisade-js","path":"/palisade","result":{"data":{"page":{"label":"Palisade","url":"/palisade","title":"PALISADE study: Phase 3 clinical trial rigorously studied PALFORZIA","header":{"title":"PALISADE study: Phase 3 clinical trial rigorously studied PALFORZIA","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."},{"title":"The PALISADE Group of Clinical Investigators: Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001."}]},"content":[{"__typename":"ContentfulHcpMenu","label":"Palisade Study","menuElements":[{"__typename":"ContentfulHcpNavigationElement","label":"Study Design","action":{"type":"ContentfulHcpPalisadeCardA","title":"Duration","header":{"title":"Duration of trial was 12 months with food challenges at entry and exit","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."},{"title":"The PALISADE Group of Clinical Investigators: Vickery BP, Vereda A, Casale TB, et al. Protocol for: AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001."}]},"content":[{"title":"Entry","figure":"Entry DBPCFC","figureSubtext":null,"footnote":"Entry food challenge was required only in the PALISADE study, providing a baseline comparator for results at treatment end.","caption":{"internal":{"content":"Consisted of 5 dose levels ranged from 1 mg to 100 mg"}}},{"title":"Initial Dose","figure":"Initial Dose Escalation","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"In-office visit with gradual dose increasing from 0.5 mg to 6 mg"}}},{"title":"Up-Dosing","figure":"Up-Dosing","figureSubtext":"~6 months","footnote":null,"caption":{"internal":{"content":"Daily home dosing with in-office dose escalation every ~2 weeks (11 times) until 300 mg is achieved"}}},{"title":"Maintenance","figure":"Maintenance Dosing","figureSubtext":"6 months","footnote":null,"caption":{"internal":{"content":"Daily 300-mg dose taken at home"}}},{"title":"Exit","figure":"Exit DBPCFC","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"Primary endpoint to measure desensitization; dose levels ranged from 3 mg to 1000 mg of peanut protein"}}}],"footer":{"title":"DBPCFC","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"DBPCFC = double-blind, placebo-controlled food challenge.","marks":[],"data":{}}],"data":{}}]}},"references":null,"figure":null,"footnote":null,"order":null}},"image":null,"showIcon":null},{"__typename":"ContentfulHcpNavigationElement","label":"Efficacy","action":{"type":"ContentfulHcpPalisadeCardA","title":"Duration","header":{"title":"Duration of trial was 12 months with food challenges at entry and exit","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."},{"title":"The PALISADE Group of Clinical Investigators: Vickery BP, Vereda A, Casale TB, et al. Protocol for: AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001."}]},"content":[{"title":"Entry","figure":"Entry DBPCFC","figureSubtext":null,"footnote":"Entry food challenge was required only in the PALISADE study, providing a baseline comparator for results at treatment end.","caption":{"internal":{"content":"Consisted of 5 dose levels ranged from 1 mg to 100 mg"}}},{"title":"Initial Dose","figure":"Initial Dose Escalation","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"In-office visit with gradual dose increasing from 0.5 mg to 6 mg"}}},{"title":"Up-Dosing","figure":"Up-Dosing","figureSubtext":"~6 months","footnote":null,"caption":{"internal":{"content":"Daily home dosing with in-office dose escalation every ~2 weeks (11 times) until 300 mg is achieved"}}},{"title":"Maintenance","figure":"Maintenance Dosing","figureSubtext":"6 months","footnote":null,"caption":{"internal":{"content":"Daily 300-mg dose taken at home"}}},{"title":"Exit","figure":"Exit DBPCFC","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"Primary endpoint to measure desensitization; dose levels ranged from 3 mg to 1000 mg of peanut protein"}}}],"footer":{"title":"DBPCFC","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"DBPCFC = double-blind, placebo-controlled food challenge.","marks":[],"data":{}}],"data":{}}]}},"references":null,"figure":null,"footnote":null,"order":null}},"image":null,"showIcon":null},{"__typename":"ContentfulHcpNavigationElement","label":"Safety","action":{"type":"ContentfulHcpPalisadeCardA","title":"Duration","header":{"title":"Duration of trial was 12 months with food challenges at entry and exit","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."},{"title":"The PALISADE Group of Clinical Investigators: Vickery BP, Vereda A, Casale TB, et al. Protocol for: AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001."}]},"content":[{"title":"Entry","figure":"Entry DBPCFC","figureSubtext":null,"footnote":"Entry food challenge was required only in the PALISADE study, providing a baseline comparator for results at treatment end.","caption":{"internal":{"content":"Consisted of 5 dose levels ranged from 1 mg to 100 mg"}}},{"title":"Initial Dose","figure":"Initial Dose Escalation","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"In-office visit with gradual dose increasing from 0.5 mg to 6 mg"}}},{"title":"Up-Dosing","figure":"Up-Dosing","figureSubtext":"~6 months","footnote":null,"caption":{"internal":{"content":"Daily home dosing with in-office dose escalation every ~2 weeks (11 times) until 300 mg is achieved"}}},{"title":"Maintenance","figure":"Maintenance Dosing","figureSubtext":"6 months","footnote":null,"caption":{"internal":{"content":"Daily 300-mg dose taken at home"}}},{"title":"Exit","figure":"Exit DBPCFC","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"Primary endpoint to measure desensitization; dose levels ranged from 3 mg to 1000 mg of peanut protein"}}}],"footer":{"title":"DBPCFC","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"DBPCFC = double-blind, placebo-controlled food challenge.","marks":[],"data":{}}],"data":{}}]}},"references":null,"figure":null,"footnote":null,"order":null}},"image":null,"showIcon":null}]},{"__typename":"ContentfulHcpPalisadeCardA","title":"Duration","header":{"title":"Duration of trial was 12 months with food challenges at entry and exit","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."},{"title":"The PALISADE Group of Clinical Investigators: Vickery BP, Vereda A, Casale TB, et al. Protocol for: AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001."}]},"content":[{"title":"Entry","figure":"Entry DBPCFC","figureSubtext":null,"footnote":"Entry food challenge was required only in the PALISADE study, providing a baseline comparator for results at treatment end.","caption":{"internal":{"content":"Consisted of 5 dose levels ranged from 1 mg to 100 mg"}}},{"title":"Initial Dose","figure":"Initial Dose Escalation","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"In-office visit with gradual dose increasing from 0.5 mg to 6 mg"}}},{"title":"Up-Dosing","figure":"Up-Dosing","figureSubtext":"~6 months","footnote":null,"caption":{"internal":{"content":"Daily home dosing with in-office dose escalation every ~2 weeks (11 times) until 300 mg is achieved"}}},{"title":"Maintenance","figure":"Maintenance Dosing","figureSubtext":"6 months","footnote":null,"caption":{"internal":{"content":"Daily 300-mg dose taken at home"}}},{"title":"Exit","figure":"Exit DBPCFC","figureSubtext":null,"footnote":null,"caption":{"internal":{"content":"Primary endpoint to measure desensitization; dose levels ranged from 3 mg to 1000 mg of peanut protein"}}}],"footer":{"title":"DBPCFC","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"DBPCFC = double-blind, placebo-controlled food challenge.","marks":[],"data":{}}],"data":{}}]}},"references":null,"figure":null,"footnote":null,"order":null}}],"referencesHeader":{"title":"References","references":null}}},"pageContext":{"maxWidths":[1140,960,720,540],"xlDevice":1200,"lgDevice":992,"mdDevice":768,"smDevice":576}}}